Roche’s Alecensa wins EU panel’s nod against mutated lung cancer

Share this post

ZURICH (Reuters) – Swiss drugmaker Roche’s Alecensa has been recommended for approval in Europe as a first-line treatment for mutated lung cancer, a key European Medicines Agency (ESA) experts panel said on Friday.

This post was syndicated from Reuters: Health News. Click here to read the full text on the original website.

Share this post

Be the first to comment

Leave a Reply